Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

How France will distribute COVID-19 vaccines

12/08/2020 | 12:42pm EDT

PARIS, Dec 8 (Reuters) - France is preparing the rollout of a first round of COVID-19 vaccines that it hopes will start reaching the most at risk citizens early next year pending regulatory approvals of the European Medicines Agency (EMA).

The government will ensure vaccines are free for all in its social security system and has earmarked 1.5 billion euros ($1.8 billion) of next year's budget to cover costs, Prime Minister Jean Castex said on Thursday.

Castex, who confirmed vaccination would not be made compulsory, urged all citizens to get a shot.

The task appears particularly daunting in a country where hostility toward vaccination is well rooted.

According to an Ipsos poll for the World Economic Forum, only 59% of French respondents said they would get a COVID-19 vaccine if it became available, compared with 67% in the United States and 85% in Britain.

WHEN IS REGULATORY APPROVAL EXPECTED?

The EMA has set a Dec. 29 deadline to decide on a Pfizer /BioNTech candidate and Jan. 12 for a vaccine developed by Moderna.

Castex said on Thursday France's top public health advisory body, Haute Autorite de Sante, would also subsequently deliver its advice before any vaccine can be distributed.

WHEN WILL VACCINES START ARRIVING?

The government has said it would be ready to start providing shots as soon as a vaccine gets approved which means its vaccination campaign could start as early as January 2021.

France, through the European Union, has secured some 200 million doses Castex said, enough to vaccinate some 100 million with a two doses regimen - more than the country's population estimated at 67 million.

WHO WILL RECEIVE THE FIRST DOSES?

The government has laid out a vaccination calendar with three main stages.

A first phase running through February would see vaccines given to nursing home residents and some of the staff looking after them, representing a population of about 1 million.

Synerpa, France's largest federation of private nursing homes, said it expected to start vaccinating residents from mid-January.

A second phase starting in March would see some 14 million receive the shot based on age and medical criteria.

A third phase beginning in the spring of 2021 would then target the rest of the adult population gradually.

HOW WILL VACCINES BE TRANSPORTED AND TO WHERE?

French health minister Olivier Veran said two distinct logistics circuits had been setup to ensure France's 10,000 nursing homes receive the vaccines smoothly, including the Pfizer-BioNTech jabs which need to be stored at temperatures of -70 degrees Celsius.

Once they depart manufacturing sites, the vaccines would be stored in dedicated pharmaceutical warehouses, Veran said, before reaching hospitals and nursing homes.

Veran said special freezers and the necessary equipment such as syringes had been purchased to deliver the vaccine across the country without giving specifics, adding arrangements had also been made for access in French overseas territories.

WHO WILL BE IN CHARGE OF ADMINISTERING VACCINES TO PEOPLE?

French general practitioners will be entitled to administer vaccines. Other local health workers will also be involved depending on the approval timeframe of vaccines throughout 2021.

For nursing homes residents, a consultation prior to vaccination and a medical follow up post vaccination will be organised.

(Reporting by Matthias Blamont Editing by Keith Weir)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.53% 238.55 Delayed Quote.192.63%
IPSOS 0.29% 34.3 Real-time Quote.24.28%
MODERNA, INC. 0.85% 218.85 Delayed Quote.109.49%
All news about MODERNA, INC.
06/11MODERNA  : More Moderna vaccine on the way to B.C. as adults with first dose top..
AQ
06/11MODERNA  : U.S. administers 306.5 mln doses of COVID-19 vaccines - CDC
RE
06/11MODERNA  : U.S. CDC Says Administered 306,509,795 Doses Of Covid-19 Vaccine As O..
RE
06/11MODERNA, GAMESTOP, AMAZON.COM : Stocks That Defined the Week
DJ
06/11MODERNA  : Statement on Myocarditis and Pericarditis
PU
06/11FDA Approves Export of Covid-19 Vaccine Doses From Troubled Baltimore Plan --..
DJ
06/11European Shares Rise as UK GDP Tops Estimates
MT
06/11FDA Approves Export of Covid-19 Vaccine Doses from Troubled Baltimore Plant
DJ
06/11MODERNA  : Signs COVID-19 Vaccine Commercialization Agreement In Saudi Arabia
MT
06/11MODERNA  : European Medicines Agency's OKs New Facility in France To Produce Mod..
MT
More news
Financials (USD)
Sales 2021 18 604 M - -
Net income 2021 10 714 M - -
Net cash 2021 11 520 M - -
P/E ratio 2021 8,88x
Yield 2021 -
Capitalization 87 874 M 87 874 M -
EV / Sales 2021 4,10x
EV / Sales 2022 4,22x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 168,87 $
Last Close Price 218,85 $
Spread / Highest target 12,4%
Spread / Average Target -22,8%
Spread / Lowest Target -62,1%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.109.49%87 874
LONZA GROUP AG16.32%54 656
IQVIA HOLDINGS INC.35.87%46 658
CELLTRION, INC.-26.04%32 458
SEAGEN INC.-10.60%28 416
HANGZHOU TIGERMED CONSULTING CO., LTD13.85%24 128